Sofia M. Perez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sofia M. Perez has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Antonella Tosti
Dr Philip Frost Department of Dermatology and Cutaneous Surgery
10 shared publicationsBetty Nguyen
4 shared publications- Antonella Tosti
University of Miami Miller School of Medicine
3 shared publications - Betty Nguyen
Dr Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA
3 shared publications - Ralf Paus
Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33125, USA
3 shared publications Marina Landau
Arena Dermatology and Department of Plastic Surgery, Shamir Medical Center, Be’er Ya’akov, Israel
2 shared publications
Latest Publications
- 19 March 2026
- Published by Wolters Kluwer Health in Annals of Plastic Surgery
- Vol. 96 (5) , 404-412
Implications of Dermatologic Disorders in Facial Cosmetic Surgery
Background: Invasive and minimally invasive cosmetic procedures in patients with autoimmune or inflammatory skin disorders can carry an increased risk of surgical site infection, disease exacerbation, atrophic/hypertrophic scarring, or suboptimal cosmetic results. As facial procedures continue to rise in popularity, increasing complications are being reported in association with underlying dermatologic disease. In this review, we aim to bring attention to these dermatologic conditions and the potential challenges that they pose to the facial plastic surgeon. Methods: A comprehensive literature search was conducted across PubMed, Embase, and MEDLINE for articles published before January 2025 describing one or more patients with complications following facial or scalp procedures relating to a pre-existing or underlying dermatologic disorder or systemic condition with dermatologic manifestations. Articles were screened according to PRISMA guidelines, and data extraction included dermatologic disease diagnosis and severity, facial procedure performed, perioperative or postoperative complications, and resolution/treatment. Results: Our search criteria identified 2452 articles; 53 articles met the inclusion criteria. In a total of 469 patients with pre-existing dermatologic conditions, mild-severe complications were reported after blepharoplasty (41/469, 8.7%), rhinoplasty (254/469, 54.2%), rhytidectomy (25/469, 5.3%), hair transplantation (37/469, 7.9%), cosmetic injections (35/469, 7.5%), lasers (15/469, 3.2%), and microneedling (50/469, 10.7%). Dermatologic disorders included acne, atopic dermatitis, frontal fibrosing alopecia, lichen planopilaris, rosacea, and vitiligo; systemic conditions with dermatologic manifestations included Ehlers-Danlos syndrome, sarcoidosis, scleroderma, and systemic or discoid lupus erythematosus. Complications ranged from mild postoperative disease exacerbation to severe hypertrophic scarring, ulcerations, and wound healing defects. Conclusions: The existing literature, while limited to case reports and small case series, demonstrates potential risks following facial procedures in patients with dermatologic disorders. This review highlights the importance of consideration of dermatologic disease in facial surgery planning and decision-making and summarizes effective strategies to minimize any potential risk.
- 19 March 2026
- Published by Wolters Kluwer Health in Annals of Plastic Surgery
- Vol. 96 (5) , 404-412
Implications of Dermatologic Disorders in Facial Cosmetic Surgery
Background: Invasive and minimally invasive cosmetic procedures in patients with autoimmune or inflammatory skin disorders can carry an increased risk of surgical site infection, disease exacerbation, atrophic/hypertrophic scarring, or suboptimal cosmetic results. As facial procedures continue to rise in popularity, increasing complications are being reported in association with underlying dermatologic disease. In this review, we aim to bring attention to these dermatologic conditions and the potential challenges that they pose to the facial plastic surgeon. Methods: A comprehensive literature search was conducted across PubMed, Embase, and MEDLINE for articles published before January 2025 describing one or more patients with complications following facial or scalp procedures relating to a pre-existing or underlying dermatologic disorder or systemic condition with dermatologic manifestations. Articles were screened according to PRISMA guidelines, and data extraction included dermatologic disease diagnosis and severity, facial procedure performed, perioperative or postoperative complications, and resolution/treatment. Results: Our search criteria identified 2452 articles; 53 articles met the inclusion criteria. In a total of 469 patients with pre-existing dermatologic conditions, mild-severe complications were reported after blepharoplasty (41/469, 8.7%), rhinoplasty (254/469, 54.2%), rhytidectomy (25/469, 5.3%), hair transplantation (37/469, 7.9%), cosmetic injections (35/469, 7.5%), lasers (15/469, 3.2%), and microneedling (50/469, 10.7%). Dermatologic disorders included acne, atopic dermatitis, frontal fibrosing alopecia, lichen planopilaris, rosacea, and vitiligo; systemic conditions with dermatologic manifestations included Ehlers-Danlos syndrome, sarcoidosis, scleroderma, and systemic or discoid lupus erythematosus. Complications ranged from mild postoperative disease exacerbation to severe hypertrophic scarring, ulcerations, and wound healing defects. Conclusions: The existing literature, while limited to case reports and small case series, demonstrates potential risks following facial procedures in patients with dermatologic disorders. This review highlights the importance of consideration of dermatologic disease in facial surgery planning and decision-making and summarizes effective strategies to minimize any potential risk.
- Open Access
- 13 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (16) , 7811
IL-15 Promotes the Survival of Anti-Inflammatory (M2), Immunoinhibitory (IL-10+) Dermal Macrophages in Human Eyelid Skin Under IFNγ-Dominated Inflammatory Conditions
Interleukin (IL)-15 is primarily known as a pro-inflammatory and anti-apoptotic cytokine, which stimulates the proliferation and survival of key immunocytes, including macrophages (MACs). Yet, it remains unclear how IL-15 specifically impacts MACs in intact human skin, particularly immunoinhibitory, IL-10-producing/secreting M2 MACs (CD206+IL-10+). In the current pilot study, we explored this in organ-cultured healthy human eyelid skin in the presence of IFNγ (100 IU/mL) to mimic a pro-inflammatory signaling milieu found in several chronic immunodermatoses. Quantitative immunohistomorphometry showed that IFNγ significantly reduced the number of CD68+MACs, M2 CD206+MACs, and immunoinhibitory CD206+IL-10+MACs. Moreover, co-administering recombinant human (rh) IL-15 after inducing inflammation by IFNγ largely reversed the IFNγ-induced decline in MAC populations. To investigate if this was mediated via the private IL-15 receptor alpha (IL-15Rα), we successfully silenced IL-15Rα in human skin ex vivo. Indeed, co-administration of IL-15Rα siRNA abrogated the rhIL-15 protection of M2 CD206+MACs against IFNγ, but not of the CD206+IL-10+MAC subpopulation. These pilot data suggest that IL-15 maintains immunoinhibitory M2 CD206+IL-10+MACs in human skin under IFNγ-dominated inflammatory conditions. Therefore, it deserves to be explored whether IL-15 or IL-15Rα agonists can exert therapeutic benefit in chronic inflammatory dermatoses by preserving the intracutaneous pool of anti-inflammatory dermal M2 MACs.
- 13 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (16) , 7811
Open AccessIL-15 Promotes the Survival of Anti-Inflammatory (M2), Immunoinhibitory (IL-10+) Dermal Macrophages in Human Eyelid Skin Under IFNγ-Dominated Inflammatory Conditions
Interleukin (IL)-15 is primarily known as a pro-inflammatory and anti-apoptotic cytokine, which stimulates the proliferation and survival of key immunocytes, including macrophages (MACs). Yet, it remains unclear how IL-15 specifically impacts MACs in intact human skin, particularly immunoinhibitory, IL-10-producing/secreting M2 MACs (CD206+IL-10+). In the current pilot study, we explored this in organ-cultured healthy human eyelid skin in the presence of IFNγ (100 IU/mL) to mimic a pro-inflammatory signaling milieu found in several chronic immunodermatoses. Quantitative immunohistomorphometry showed that IFNγ significantly reduced the number of CD68+MACs, M2 CD206+MACs, and immunoinhibitory CD206+IL-10+MACs. Moreover, co-administering recombinant human (rh) IL-15 after inducing inflammation by IFNγ largely reversed the IFNγ-induced decline in MAC populations. To investigate if this was mediated via the private IL-15 receptor alpha (IL-15Rα), we successfully silenced IL-15Rα in human skin ex vivo. Indeed, co-administration of IL-15Rα siRNA abrogated the rhIL-15 protection of M2 CD206+MACs against IFNγ, but not of the CD206+IL-10+MAC subpopulation. These pilot data suggest that IL-15 maintains immunoinhibitory M2 CD206+IL-10+MACs in human skin under IFNγ-dominated inflammatory conditions. Therefore, it deserves to be explored whether IL-15 or IL-15Rα agonists can exert therapeutic benefit in chronic inflammatory dermatoses by preserving the intracutaneous pool of anti-inflammatory dermal M2 MACs.
- 24 July 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (11) , 2182-2184
Artificial Intelligence and Trichoscopy: Potentials and Pitfalls in Alopecia Diagnosis
- 24 July 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (11) , 2182-2184
Artificial Intelligence and Trichoscopy: Potentials and Pitfalls in Alopecia Diagnosis
- 24 June 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (10) , 2410-2416.e3
Lessons from TNF-α Inhibitor–Induced Alopecia Areata: Does TNF-α Operate as a Hair Follicle Immune Privilege Guardian under Inflammatory Conditions?
- 24 June 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (10) , 2410-2416.e3
Lessons from TNF-α Inhibitor–Induced Alopecia Areata: Does TNF-α Operate as a Hair Follicle Immune Privilege Guardian under Inflammatory Conditions?
- Open Access
Botulinum Toxin in the Treatment of Hair and Scalp Disorders: Current Evidence and Clinical Applications
Botulinum toxin (BoNT) is well-recognized throughout dermatology for its cosmetic indications and growing therapeutic value. Recent studies have trialed BoNT in the treatment of hair and scalp disorders, many of which lack long-term effective treatments and significantly impact quality of life. In this review, we summarize the current clinical literature on this topic to comprehensively evaluate the efficacy, safety, and clinical value of BoNT in treating hair and scalp conditions. A literature search on PubMed/MEDLINE and Scopus identified 40 articles reporting the use of 25–200 units of BoNT-A or B in 689 patients with hair loss (79.5%), scalp seborrheic dermatitis/hyperseborrhea (10%), craniofacial hyperhidrosis (9%), folliculitis decalvans/dissecting folliculitis (0.86%), scalp pain (0.43%), or linear scleroderma (0.29%). Most studies on BoNT therapy for androgenetic alopecia (AGA) reported mild or non-significant hair growth; however, considerable variability in outcome measures complicates the ability to draw definitive conclusions or justify the use of BoNT over established AGA therapies. BoNT-A and B showed consistent efficacy in treating craniofacial hyperhidrosis with minimal side effects. Additional scalp conditions may benefit from BoNT therapy, but the evidence is limited, and larger, controlled studies are needed to better understand BoNT’s clinical value in these conditions.
Open AccessBotulinum Toxin in the Treatment of Hair and Scalp Disorders: Current Evidence and Clinical Applications
Botulinum toxin (BoNT) is well-recognized throughout dermatology for its cosmetic indications and growing therapeutic value. Recent studies have trialed BoNT in the treatment of hair and scalp disorders, many of which lack long-term effective treatments and significantly impact quality of life. In this review, we summarize the current clinical literature on this topic to comprehensively evaluate the efficacy, safety, and clinical value of BoNT in treating hair and scalp conditions. A literature search on PubMed/MEDLINE and Scopus identified 40 articles reporting the use of 25–200 units of BoNT-A or B in 689 patients with hair loss (79.5%), scalp seborrheic dermatitis/hyperseborrhea (10%), craniofacial hyperhidrosis (9%), folliculitis decalvans/dissecting folliculitis (0.86%), scalp pain (0.43%), or linear scleroderma (0.29%). Most studies on BoNT therapy for androgenetic alopecia (AGA) reported mild or non-significant hair growth; however, considerable variability in outcome measures complicates the ability to draw definitive conclusions or justify the use of BoNT over established AGA therapies. BoNT-A and B showed consistent efficacy in treating craniofacial hyperhidrosis with minimal side effects. Additional scalp conditions may benefit from BoNT therapy, but the evidence is limited, and larger, controlled studies are needed to better understand BoNT’s clinical value in these conditions.
- Open Access
- 8 March 2025
- Published by Elsevier in JAAD Reviews
- Vol. 4, 61-68
Efficacy and safety of bicalutamide in female hair loss: A review of the literature
- 8 March 2025
- Published by Elsevier in JAAD Reviews
- Vol. 4, 61-68
Open AccessEfficacy and safety of bicalutamide in female hair loss: A review of the literature
- Open Access
- 29 November 2024
- Published by Elsevier in JAAD Reviews
- Vol. 3, 6-17
Drug-induced hair pigmentation: Clinical perspectives and updates
- 29 November 2024
- Published by Elsevier in JAAD Reviews
- Vol. 3, 6-17
Open AccessDrug-induced hair pigmentation: Clinical perspectives and updates
- Open Access
- 28 November 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (1) , 15-29
Frontal Fibrosing Alopecia: A Comprehensive Guide for Cosmetic Dermatologists
Frontal fibrosing alopecia (FFA) is an inflammatory, scarring hair loss that commonly affects postmenopausal women and presents as frontal hairline recession, facial papules, loss of eyebrows, and facial hyperpigmentation. Because of the chronic, progressive nature of this disease and its important impact on aesthetic appearance, patients often consult dermatologists to improve unwanted FFA symptoms. Cosmetic practices including the use of non-ablative lasers, autologous fat injections, and oral isotretinoin can improve FFA-associated facial vein prominence, atrophic indentations, and facial papules, respectively. On the other hand, while exact etiology underlying FFA development remains unclear, some procedures including deep chemical peels and ablative laser therapies have been shown to induce facial scarring and are contraindicated in patients with FFA. In the same way, some cosmetic ingredients can possibly be a triggering or worsening factor for FFA as well. Therefore, it is essential for dermatologists to be aware of both the benefits and risks of cosmetic treatments in patients with diagnosed or suspected FFA. This comprehensive review aims to outline the key cosmetic products and procedures that may be useful in patients with FFA and those which should be considered contraindicated.
- 28 November 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (1) , 15-29
Open AccessFrontal Fibrosing Alopecia: A Comprehensive Guide for Cosmetic Dermatologists
Frontal fibrosing alopecia (FFA) is an inflammatory, scarring hair loss that commonly affects postmenopausal women and presents as frontal hairline recession, facial papules, loss of eyebrows, and facial hyperpigmentation. Because of the chronic, progressive nature of this disease and its important impact on aesthetic appearance, patients often consult dermatologists to improve unwanted FFA symptoms. Cosmetic practices including the use of non-ablative lasers, autologous fat injections, and oral isotretinoin can improve FFA-associated facial vein prominence, atrophic indentations, and facial papules, respectively. On the other hand, while exact etiology underlying FFA development remains unclear, some procedures including deep chemical peels and ablative laser therapies have been shown to induce facial scarring and are contraindicated in patients with FFA. In the same way, some cosmetic ingredients can possibly be a triggering or worsening factor for FFA as well. Therefore, it is essential for dermatologists to be aware of both the benefits and risks of cosmetic treatments in patients with diagnosed or suspected FFA. This comprehensive review aims to outline the key cosmetic products and procedures that may be useful in patients with FFA and those which should be considered contraindicated.
- 26 October 2024
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 316 (10) , 1-4
Efficacy of vibration anesthesia in facial injections: a systematic review and meta-analysis
- 26 October 2024
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 316 (10) , 1-4
Efficacy of vibration anesthesia in facial injections: a systematic review and meta-analysis
- 15 October 2024
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 51 (2) , 179-183
Low-Level Laser and LED Therapy in Alopecia: A Systematic Review and Meta-Analysis
BACKGROUND: Low-level laser/LED therapy (LLLT) has been described as a treatment option for alopecia, but no study has comprehensively reviewed its efficacy in multiple alopecia types. OBJECTIVE: To review and evaluate LLLT for various alopecia types. MATERIALS AND METHODS: A systematic search of PubMed/MEDLINE, Embase, and CENTRAL was conducted to identify studies assessing the effect of LLLT on patients diagnosed with alopecia. Prespecified outcome measure was the change in hair density. Meta-analysis was performed to calculate the standardized mean difference in hair density before and after LLLT compared with placebo. RESULTS: Thirty-eight studies were included that described 3,098 patients with androgenetic alopecia (2,930/3,098), scarring alopecia (49/3,098), alopecia areata (50/3,098), telogen effluvium (17/3,098), and chemotherapy-induced alopecia (32/3,098). The mean change in hair density increased significantly in androgenetic alopecia patients after LLLT for 4 to 26 weeks compared with placebo (20 weeks: SMD = 1.44; 95% CI [0.97–1.91]; p = .000; I2 = 80.81%). Change in hair density was reported in 5 studies evaluating other alopecia types; however, statistical information was insufficient for meta-analysis. CONCLUSION: LLLT is a promising treatment option for patients with androgenetic alopecia, but future studies are needed to better understand its efficacy in other alopecia types.
- 15 October 2024
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 51 (2) , 179-183
Low-Level Laser and LED Therapy in Alopecia: A Systematic Review and Meta-Analysis
BACKGROUND: Low-level laser/LED therapy (LLLT) has been described as a treatment option for alopecia, but no study has comprehensively reviewed its efficacy in multiple alopecia types. OBJECTIVE: To review and evaluate LLLT for various alopecia types. MATERIALS AND METHODS: A systematic search of PubMed/MEDLINE, Embase, and CENTRAL was conducted to identify studies assessing the effect of LLLT on patients diagnosed with alopecia. Prespecified outcome measure was the change in hair density. Meta-analysis was performed to calculate the standardized mean difference in hair density before and after LLLT compared with placebo. RESULTS: Thirty-eight studies were included that described 3,098 patients with androgenetic alopecia (2,930/3,098), scarring alopecia (49/3,098), alopecia areata (50/3,098), telogen effluvium (17/3,098), and chemotherapy-induced alopecia (32/3,098). The mean change in hair density increased significantly in androgenetic alopecia patients after LLLT for 4 to 26 weeks compared with placebo (20 weeks: SMD = 1.44; 95% CI [0.97–1.91]; p = .000; I2 = 80.81%). Change in hair density was reported in 5 studies evaluating other alopecia types; however, statistical information was insufficient for meta-analysis. CONCLUSION: LLLT is a promising treatment option for patients with androgenetic alopecia, but future studies are needed to better understand its efficacy in other alopecia types.